Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Bendiske

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Neurochemistry|October 23, 2002
The neuropathogenic contributions of lysosomal dysfunctionBen A Bahr, Jennifer Bendiske
Journal of Neuropathology and Experimental Neurology|May 29, 2003
Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis--an approach for slowing Alzheimer disease?Jennifer Bendiske, Ben A Bahr
Journal of Neuropathology and Experimental Neurology|July 20, 2002
Intracellular deposition, microtubule destabilization, and transport failure: an "early" pathogenic cascade leading to synaptic declineJennifer Bendiske, Ebru Caba, Queenie B Brown, et al.
European Journal of Pharmacology|March 6, 2007
Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markersDavid Butler, Jennifer Bendiske, Mary L Michaelis, et al.
Experimental Neurology|March 1, 2002
Survival signaling and selective neuroprotection through glutamatergic transmissionBen A Bahr, Jennifer Bendiske, Queenie B Brown, et al.
Journal of Neuropathology and Experimental Neurology|September 7, 2007
Lysosomal dysfunction produces distinct alterations in synaptic alpha-amino-3-hydroxy-5-methylisoxazolepropionic acid and N-methyl-D-aspartate receptor currents in hippocampusPatrick M Kanju, Kodeeswaran Parameshwaran, Thirumalini Vaithianathan, et al.
Leukemia & Lymphoma|April 6, 2012
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Neurochemistry|October 23, 2002
The neuropathogenic contributions of lysosomal dysfunctionBen A Bahr, Jennifer Bendiske
Journal of Neuropathology and Experimental Neurology|May 29, 2003
Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis--an approach for slowing Alzheimer disease?Jennifer Bendiske, Ben A Bahr
Journal of Neuropathology and Experimental Neurology|July 20, 2002
Intracellular deposition, microtubule destabilization, and transport failure: an "early" pathogenic cascade leading to synaptic declineJennifer Bendiske, Ebru Caba, Queenie B Brown, et al.
European Journal of Pharmacology|March 6, 2007
Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markersDavid Butler, Jennifer Bendiske, Mary L Michaelis, et al.
Experimental Neurology|March 1, 2002
Survival signaling and selective neuroprotection through glutamatergic transmissionBen A Bahr, Jennifer Bendiske, Queenie B Brown, et al.
Journal of Neuropathology and Experimental Neurology|September 7, 2007
Lysosomal dysfunction produces distinct alterations in synaptic alpha-amino-3-hydroxy-5-methylisoxazolepropionic acid and N-methyl-D-aspartate receptor currents in hippocampusPatrick M Kanju, Kodeeswaran Parameshwaran, Thirumalini Vaithianathan, et al.
Leukemia & Lymphoma|April 6, 2012
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
JCO Precision Oncology|February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR AlterationsDavid M Hyman, Ben Tran, Luis Paz-Ares, et al.
Pageof 1